Physician profile
Caesar K Tin-U
NPI 1609814615
$6,163.08
in general payments reported to CMS, 2019-2025
28 companies · $843 in 2025
The $843 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,748 · 2020: $26.61 · 2021: $13.13 · 2022: $265 · 2023: $149 · 2024: $117 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,010 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,010.04 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $4,567.29 | 2019 | |
| Janssen Biotech, INC. | $240.10 | 2022-2025 | Darzalex, Rybrevant, Erleada |
| Astellas Pharma US INC | $224.63 | 2019-2025 | Xtandi |
| Daiichi Sankyo INC. | $179.49 | 2025 | Datroway, Enhertu |
| Novartis Pharmaceuticals Corporation | $176.52 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $150.16 | 2022-2025 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $100.95 | 2022 | |
| Pfizer INC. | $86.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $55.90 | 2025 | Enhertu, Tagrisso |
| Celgene Corporation | $55.51 | 2025 | Reblozyl, Opdivo |
| Stemline Therapeutics INC. | $49.50 | 2025 | Orserdu |
| Tempus Ai, INC | $43.52 | 2024 | |
| Taiho Oncology, INC. | $41.48 | 2025 | |
| Exelixis INC. | $38.29 | 2019 | |
| Merck Sharp & Dohme LLC | $34.18 | 2025 | Lynparza, Keytruda |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $32.74 | 2025 | Brukinsa |
| Eisai INC. | $29.44 | 2024 | |
| Beigene USA, INC. | $23.18 | 2024 | Brukinsa |
| Abbvie INC. | $18.36 | 2025 | |
| Amgen INC. | $13.13 | 2021 | |
| Janssen Pharmaceuticals, INC | $2.34 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caesar Tin-U listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.